

## **ten23 health® and Ypsomed collaborate on the commercialization of the YpsoDose patch injector**

**Burgdorf & Basel, 16 April .2024, ten23 health® and Ypsomed today announced that they are entering into a strategic partnership to advance the commercialization of the YpsoDose wearable injector for subcutaneous self-injection of large-volume doses.**

ten23 health®, a CDMO focused on the sustainable development and manufacture of modern medicines, and Ypsomed, leading developer of injection and infusion systems for self-medication, have entered a strategic collaboration. Both parties will proactively invest in technology and infrastructure to offer the YpsoDose patch injector platform as a fully integrated solution for the subcutaneous self-administration of large volume injectables.

This comprehensive solution includes a ready-to-use cartriQ glass cartridge from SCHOTT Pharma as the primary packaging for the drug, the YpsoDose patch injector platform from Ypsomed, and formulation and process development, filling, assembly, and testing (QC) of the final product by ten23 health. Pharmaceutical customers will have the option to receive a rigorously tested and documented overall solution, which will significantly accelerate time to clinic, and subsequently time to market, allowing them to concentrate on their core initiatives.

This collaboration will harness ten23 health's expertise in the development, manufacturing and testing of complex formulations for subcutaneous administration while leveraging their comprehensive experience in the clinical and commercial fill & finish of complex dosage forms, including large volume cartridges for devices. ten23 health is well positioned to meet specific and unique requirements.

“This exciting partnership with Ypsomed aligns seamlessly with our vision of a successful drug product in which the drug-device integration is taken into account from the very beginning of its design – where formulation, primary packaging, and medical devices are equally important parts, providing stable, safe, usable and effective medicines to patients,” says **Prof. Dr. Hanns-Christian Mahler**, Chief Enablement Officer at ten23 health.

Ypsomed's platform enables its customers to have considerable freedom in the choice of components and partners to implement their own processes as needed.

The integrated solution provided by the collaborating partners allows them to leverage knowledge and to collaborate throughout all necessary steps and components for an overall shortened time-to-market and reduced development risks of the biopharmaceutical drug/device combination product.

“Together with ten23 as strong partner, we offer a comprehensive solution, for our customers to bring their medicines to market as a commercially viable and competitive product in a short time, at a lower cost and with low risks,” says **Reto Jost**, Category Lead Large Volume Injectors at Ypsomed.

### **About Ypsomed**

Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist. The company will celebrate its 40th anniversary in 2024. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brand mylife Diabetescare directly to patients, pharmacies, and hospitals as well as under Ypsomed Delivery Systems in business-to-business operations with pharmaceutical companies. Ypsomed is headquartered in Burgdorf, Switzerland. The company has a global network of production facilities, subsidiaries, and distribution partners. Ypsomed has over 2,200 employees worldwide.

### **About ten23 health®**

ten23 health®, located in Basel and Visp, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients. Our second site, located in Visp, Switzerland, is a world leader in the sterile production of complex pharmaceutical dosage forms and a wholly owned subsidiary of ten23 health®.

ten23 health® combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people's health and the future of our planet. ten23 health is solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

### **Media contacts:**

**ten23 health:** Mara Willa, [mara.willa@ten23.health](mailto:mara.willa@ten23.health); +41 79 489 39 05

**Ypsomed:** Susanne Koehler, [susanne.koehler@ypsomed.com](mailto:susanne.koehler@ypsomed.com); +41 34 424 47 32